Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 11/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.64 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2912939 | 0.95 | CSF1R (0.71) | CSF1RKCNH2SCN5AGAAMAPT | |
| SCHEMBL2904648 | 0.92 | CSF1R (0.79) | CSF1RKCNH2SCN5AGAAMEN1 | |
| SCHEMBL2909680 | 0.92 | CSF1R (0.79) | CSF1RKCNH2SCN5AGAAMAPT | |
| SCHEMBL2911044 | 0.91 | CSF1R (0.69) | CSF1RKCNH2SCN5AGAAMEN1 | |
| SCHEMBL2911256 | 0.89 | KCNH2 (0.76) | CSF1RKCNH2SCN5AGAAMEN1 | |
| SCHEMBL2909850 | 0.89 | CSF1R (0.66) | CSF1RKCNH2SCN5AGAAMAPT | |
| SCHEMBL2912249 | 0.89 | KCNH2 (0.64) | CSF1RKCNH2SCN5AGAAMAPT | |
| SCHEMBL2909797 | 0.89 | CSF1R (0.85) | CSF1RKCNH2SCN5A | |
| SCHEMBL2914041 | 0.88 | CSF1R (0.69) | CSF1RKCNH2SCN5AGAAMAPT | |
| SCHEMBL2905267 | 0.88 | KCNH2 (0.65) | CSF1RKCNH2SCN5AGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010496-B1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-08-25 | — | — | EP | disclosed |